Results 91 to 100 of about 1,427,249 (321)
Balancing Safety and Availability: A Historical Perspective on the Pace of Drug Approval, 1950s-2009. [PDF]
, 2009 BALANCING SAFETY AND AVAILABILITY: A HISTORICAL PERSPECTIVE ON THE PACE OF DRUG APPROVAL, 1950s-2009. Fabienne C. Meier-Abt and Bruno J. Strasser. Department of History of Medicine, Yale University, School of Medicine, New Haven, CT.
Meier-Abt, Fabienne C.
core +1 more source
Pharmacovigilance and expedited drug approvals [PDF]
Australian Prescriber, 2018 Pharmacovigilance is the detection and assessment of adverse events related to any drug used in clinical practice. In Australia adverse events can be reported to the Therapeutic Goods Administration. Reports are encouraged, even if the drug is old or the prescriber is only suspicious of an adverse event.
Linger, Matthew, Martin, Jennifer
openaire +3 more sources
Molecular Oncology, EarlyView.The authors analyzed the spatial distributions of gene and metabolite profiles in cervical cancer through spatial transcriptomic and spatially resolved metabolomic techniques. Pivotal genes and metabolites within these cases were then identified and validated.
Lixiu Xu +3 more
wiley +1 more source
Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data [PDF]
arXiv, 2020 Coronavirus disease 2019 (COVID-19) has impacted almost every part of human life worldwide, posing a massive threat to human health. There is no specific drug for COVID-19, highlighting the urgent need for the development of effective therapeutics. To identify potentially repurposable drugs, we employed a systematic approach to mine candidates from U.S.
arxiv
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics [PDF]
arXiv, 2020 The recent global pandemic of Coronavirus Disease 2019 (COVID-19) caused by the new coronavirus SARS-CoV-2 presents an urgent need for new therapeutic candidates. Many efforts have been devoted to screening existing drug libraries with the hope to repurpose approved drugs as potential treatments for COVID-19. However, the antiviral mechanisms of action
arxiv
Fluoroquinolones and tendon disorders [PDF]
, 2001 Since the 'thalidomide disaster' in 1961, there is extensive national and intemationallegisiation for the registration and monitoring of drugs. The current drug approval process in most developed countries includes pre-clinical animal testing followed
Linden, P.D. (Paul) van der
core +1 more source
Molecular Oncology, EarlyView.MiR‐99a‐5p/miR‐100‐5p (functionally identical) and miR‐125b‐5p microRNAs are downregulated in malignant germ cell tumors (GCTs). Combination replenishment of these microRNAs using mimics resulted in growth inhibition in representative cell lines, with consequent downregulation of target genes involved in cell cycle (confirmed by flow cytometry) and ...
Marta Ferraresso +12 more
wiley +1 more source
Current landscape of clinical development and approval of advanced therapies
Molecular Therapy: Methods & Clinical Development, 2021 Advanced therapy medicinal products (ATMPs) are innovative therapies that mainly target orphan diseases and high unmet medical needs. The uncertainty about the product's benefit-risk balance at the time of approval, the limitations of nonclinical ...
Carolina Iglesias-Lopez +3 more
doaj
Molecular Oncology, EarlyView.We assessed the associations between the gut microbiota and outcome in metastatic triple‐negative breast cancer patients treated with chemotherapy alone or chemotherapy in combination with immunotherapy. Our data indicate that high gut microbiota alpha diversity was associated with improved clinical outcome and with benefit from immunotherapy.
Andreas Ullern +8 more
wiley +1 more source